Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Sep 18 - Sep 23
Deficiency of core fucosylation activates cellular signaling dependent on FLT3 expression in a Ba/F3 cell system
1034148-04-3
1345847-93-9
The Quad Pill was approved by the FDA in August 2012 for use in the United States and is owned by Gilead Sciences
7 nM) and does not activate human M3 receptor (hM3)
(3S, 4S)-PF-06459988 03 (methanesulfonate) Deficiency of core fucosylation activates(3S, 4S) PF 06459988 is the S enantiomer of PF 06459988 with less active. PF 06459988 is a potent irreversible inhibitor of T790M mutant epidermal growth factor receptor (EGFR). PF 06459988 has excellent selectivity against EGFR wild type while possessing a minimally reactive electrophile that reduces the propensity of off target labeling. Product information CAS Number: 1858291 14 1 Molecular Weight: 431. 88 Formula: C19H22ClN7O3 Chemical Name: 1
US$ 260.00
US$ 302.50
US$ 42.00
US$ 40.00
US$ 235.00
US$ 162.50
US$ 17.00
US$ 285.00
US$ 25.00
US$ 215.00
US$ 15.00
US$ 180.00